Therapeutic Potential of Rexinoids in Cancer Prevention and Treatment

Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation o...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2009-06, Vol.69 (12), p.4945-4947
Main Authors: TANAKA, Takemi, DE LUCA, Luigi M
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Base Sequence
Biological and medical sciences
Humans
Ligands
Medical sciences
Neoplasms - drug therapy
Neoplasms - prevention & control
Pharmacology. Drug treatments
Retinoid X Receptors - drug effects
Retinoid X Receptors - metabolism
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-08-4407